← Back to the library

CJC-1295

peptide

often paired with Ipamorelin

Growth-hormone secretagogue (GHRH analog)

Research status · Not FDA-approved

Not FDA-approved for human use. Reached early-phase research only; available (where legal) via compounding pharmacies. Regulatory status shifted during 2025–2026 FDA compounding review — verify current status.

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) discussed in recovery, sleep, and body-composition contexts, frequently paired with ipamorelin. It is not an approved medication; human evidence is limited.

How it works

Mimics GHRH to stimulate the pituitary to release the body's own growth hormone, indirectly raising GH and IGF-1.

Commonly discussed use cases

  • Recovery (discussed)
  • Sleep quality (discussed)
  • Body composition (discussed)

Supposed / potential benefits

  • Reported subjective improvements in sleep/recovery in communities — not established in large trials

Common side effects

  • Water retention
  • Tingling/numbness
  • Headache
  • Injection-site reactions
  • Possible blood-sugar changes

Warnings & contraindications

  • Not FDA-approved; long-term safety not established
  • Raising GH/IGF-1 has theoretical risks (e.g., glucose effects, potential to affect growth of existing tumors) — a clinician-level discussion
  • Unregulated products carry purity/dosing risks

Typical timing considerations

Community/clinic discussions often mention dosing away from meals and around sleep; only a clinician should direct this.

Administration route

Subcutaneous injection

Storage

Peptides are typically refrigerated after reconstitution; follow clinician/compounding-pharmacy instructions.

Questions to ask your clinician

  • What baseline labs (IGF-1, glucose) would you want before and during?
  • How would we judge benefit vs risk objectively?
  • What would make you stop this?

Commonly tracked in Reta

Sleep ratingRecovery ratingHunger changesInjection site rotationLab dates

Tracking fields organize user-entered, clinician-directed routines — Reta never recommends or computes doses.

Sources

Track this in Reta

Beta members get a ready-made tracker for CJC-1295 — schedule, dose log, injection-site rotation, reminders, and check-ins — for organizing a clinician-directed routine. Personal tracking is available to everyone during the Public Beta.

Reta is a tracking and education tool — not a medical provider. Nothing here is a diagnosis, treatment, prescription, or dosing recommendation. Peptides and medications should only be used under the direction of a licensed clinician. Talk to a qualified clinician before starting, stopping, combining, or changing anything. Many compounds below are not FDA-approved for human use; some are investigational or sold through unregulated channels where purity and dosing are not guaranteed.